Brief: Polyphor Closing Of Fosun Pharma Licensing Agreement For Balixafortide In China

Spexis AG

29/09/2020 06:05

Sept 29 (Reuters) - POLYPHOR AG  POLN.S :
    * ANNOUNCES CLOSING OF FOSUN PHARMA LICENSING AGREEMENT FOR
BALIXAFORTIDE IN CHINA AND RECEIPT OF $15 MILLION UPFRONT
PAYMENT
    * POLYPHOR AND FOSUN PHARMA WILL DEVELOP AND COMMERCIALIZE
BALIXAFORTIDE FOR CHINESE MARKET WITH AN INITIAL FOCUS ON
METASTATIC BREAST CANCER
    * IS ELIGIBLE FOR ADDITIONAL DEVELOPMENT MILESTONE PAYMENTS
OF UP
TO $19 MILLION, SALES MILESTONE PAYMENTS OF UP TO $148 MILLION
PLUS UP TO MID-TEEN ROYALTIES ON NET SALES ACHIEVED IN TERRITORY

Source text for Eikon:  ID:nEQ44y0kba 
Further company coverage:  POLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))